Affimed N.V.
NASDAQ Global Market•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Shawn M. Leland Pharm.D., R.Ph.
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Technologiepark Heidelberg Germany 69120
- IPO Date
- Sep 12, 2014
- CIK
- 0001608390
- Website
- affimed.com
- Similar Companies
- Business
- Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Company News
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting
Affimed to Present at the Leerink Partners Global Healthcare Conference 2025
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Affimed to Present at the Cantor Global Healthcare Conference 2024
Affimed N.V. (AFMD) Q2 2024 Earnings Call Transcript
Affimed Reports Second Quarter 2024 Financial Results & Business Update
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive Catalysts
Affimed Appoints New CEO, Shares Fall on Leadership Change
Affimed Appoints Shawn M. Leland as Chief Executive Officer
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024
Affimed N.V. (AFMD) Q1 2024 Earnings Call Transcript
Affimed Reports First Quarter 2024 Financial Results & Business Update
Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024